Immunological Reviews, ISSN 0105-2896, 07/2013, Volume 254, Issue 1, pp. 225 - 244
Summary The development of an effective vaccine has been hindered by the enormous diversity of human immunodeficiency virus‐1 (HIV‐1) and its ability to escape...
unmutated ancestor (UA) | immune tolerance | monoclonal antibodies (mAbs) | broadly neutralizing antibodies (BNAbs) | B‐cell lineages | B-cell lineages | Broadly neutralizing antibodies (BNAbs) | Unmutated ancestor (UA) | Immune tolerance | Monoclonal antibodies (mAbs) | B-CELL RESPONSES | GP120 ENVELOPE GLYCOPROTEIN | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | DEFICIENCY SYNDROME AIDS | RECOMBINANT GLYCOPROTEIN-120 VACCINE | CROSS-CLADE NEUTRALIZATION | 2ND HYPERVARIABLE REGION | HUMAN MONOCLONAL-ANTIBODIES | HTLV-III LAV | SUBTYPE-B | HIV Antibodies - blood | HIV Infections - blood | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV-1 - immunology | Animals | HIV Antibodies - immunology | Humans | AIDS Vaccines - immunology | B-Lymphocyte Subsets - immunology | Research | Antibodies, Neutralizing - blood | Monoclonal antibodies | HIV (Viruses)
unmutated ancestor (UA) | immune tolerance | monoclonal antibodies (mAbs) | broadly neutralizing antibodies (BNAbs) | B‐cell lineages | B-cell lineages | Broadly neutralizing antibodies (BNAbs) | Unmutated ancestor (UA) | Immune tolerance | Monoclonal antibodies (mAbs) | B-CELL RESPONSES | GP120 ENVELOPE GLYCOPROTEIN | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | DEFICIENCY SYNDROME AIDS | RECOMBINANT GLYCOPROTEIN-120 VACCINE | CROSS-CLADE NEUTRALIZATION | 2ND HYPERVARIABLE REGION | HUMAN MONOCLONAL-ANTIBODIES | HTLV-III LAV | SUBTYPE-B | HIV Antibodies - blood | HIV Infections - blood | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV-1 - immunology | Animals | HIV Antibodies - immunology | Humans | AIDS Vaccines - immunology | B-Lymphocyte Subsets - immunology | Research | Antibodies, Neutralizing - blood | Monoclonal antibodies | HIV (Viruses)
Journal Article
Cell Host & Microbe, ISSN 1931-3128, 06/2017, Volume 21, Issue 6, pp. 777 - 787.e4
Precisely defining how viral mutations affect HIV’s sensitivity to antibodies is vital to develop and evaluate vaccines and antibody immunotherapeutics....
HIV-1 | antibody escape | broadly neutralizing antibody | PGT151 | deep mutational scanning | mutational antigenic profiling | epitope | SUPPRESSES VIREMIA | MUCOSAL SHIV CHALLENGE | PASSIVE TRANSFER | TREATMENT INTERRUPTION | MICROBIOLOGY | DRUG-RESISTANCE | FUSION PEPTIDE | DEPENDENT EPITOPE | HUMANIZED MICE | IN-VITRO | VIROLOGY | IMMUNODEFICIENCY-VIRUS TYPE-1 | PARASITOLOGY | Amino Acid Sequence | Cell Line | Epitope Mapping | env Gene Products, Human Immunodeficiency Virus - immunology | HIV Infections - virology | Humans | Neutralization Tests | Antibodies, Neutralizing - genetics | HIV-1 - genetics | Epitopes - immunology | HIV Envelope Protein gp120 - immunology | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV-1 - immunology | Polysaccharides | env Gene Products, Human Immunodeficiency Virus - genetics | Animals | HIV Antibodies - immunology | Immune Evasion - genetics | High-Throughput Nucleotide Sequencing | Mice | HIV Antibodies - genetics | Mutation | Immune Evasion - immunology | HIV antibodies | Multiprocessing | Amino acids | HIV (Viruses) | Epidemiology | Antigenic determinants
HIV-1 | antibody escape | broadly neutralizing antibody | PGT151 | deep mutational scanning | mutational antigenic profiling | epitope | SUPPRESSES VIREMIA | MUCOSAL SHIV CHALLENGE | PASSIVE TRANSFER | TREATMENT INTERRUPTION | MICROBIOLOGY | DRUG-RESISTANCE | FUSION PEPTIDE | DEPENDENT EPITOPE | HUMANIZED MICE | IN-VITRO | VIROLOGY | IMMUNODEFICIENCY-VIRUS TYPE-1 | PARASITOLOGY | Amino Acid Sequence | Cell Line | Epitope Mapping | env Gene Products, Human Immunodeficiency Virus - immunology | HIV Infections - virology | Humans | Neutralization Tests | Antibodies, Neutralizing - genetics | HIV-1 - genetics | Epitopes - immunology | HIV Envelope Protein gp120 - immunology | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV-1 - immunology | Polysaccharides | env Gene Products, Human Immunodeficiency Virus - genetics | Animals | HIV Antibodies - immunology | Immune Evasion - genetics | High-Throughput Nucleotide Sequencing | Mice | HIV Antibodies - genetics | Mutation | Immune Evasion - immunology | HIV antibodies | Multiprocessing | Amino acids | HIV (Viruses) | Epidemiology | Antigenic determinants
Journal Article
Antiviral Research, ISSN 0166-3542, 06/2013, Volume 98, Issue 3, pp. 476 - 483
Despite available antivirals and vaccines, influenza continues to be a major cause of mortality worldwide. Vaccination generally induces an effective, but...
Hemagglutinin | Influenza | Broadly neutralizing antibodies | RECOGNITION | B VIRUS | H5N1 | RECEPTOR-BINDING SITE | NEURAMINIDASE INHIBITORS | EPITOPE | VIROLOGY | A VIRUSES | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODIES | VACCINES | Antigen-Antibody Complex | Hemagglutinin Glycoproteins, Influenza Virus - chemistry | Humans | Vaccination | Antibody Affinity | Neutralization Tests | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Orthomyxoviridae - immunology | Epitopes - immunology | Antibodies, Neutralizing - immunology | Influenza Vaccines - immunology | Antibodies, Neutralizing - chemistry | Antibodies, Viral - chemistry | Drug Design | Antibodies, Viral - immunology | Protein Conformation | Epitopes - chemistry | Influenza, Human - prevention & control | Influenza, Human - immunology | Influenza viruses | Viral antibodies | Antibodies
Hemagglutinin | Influenza | Broadly neutralizing antibodies | RECOGNITION | B VIRUS | H5N1 | RECEPTOR-BINDING SITE | NEURAMINIDASE INHIBITORS | EPITOPE | VIROLOGY | A VIRUSES | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODIES | VACCINES | Antigen-Antibody Complex | Hemagglutinin Glycoproteins, Influenza Virus - chemistry | Humans | Vaccination | Antibody Affinity | Neutralization Tests | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Orthomyxoviridae - immunology | Epitopes - immunology | Antibodies, Neutralizing - immunology | Influenza Vaccines - immunology | Antibodies, Neutralizing - chemistry | Antibodies, Viral - chemistry | Drug Design | Antibodies, Viral - immunology | Protein Conformation | Epitopes - chemistry | Influenza, Human - prevention & control | Influenza, Human - immunology | Influenza viruses | Viral antibodies | Antibodies
Journal Article
Current Opinion in HIV and AIDS, ISSN 1746-630X, 07/2019, Volume 14, Issue 4, pp. 279 - 285
PURPOSE OF REVIEWBroadly neutralizing antibodies (bnAbs) are considered a key component of an effective HIV-1 vaccine, but despite intensive efforts, induction...
HIV-1 | INFECTIOUS DISEASES | HIV-1 ANTIBODY | PROTECTION | PASSIVE TRANSFER | IMMUNOLOGY | broadly neutralizing antibodies | RESPONSES | vaccine | PLASMA | SPONTANEOUS CONTROLLERS | IMMUNODEFICIENCY-VIRUS TYPE-1 | HUMORAL IMMUNITY | INFECTION | BREADTH | Viral antibodies | Antibodies | Care and treatment | Usage | HIV infection | Vaccination
HIV-1 | INFECTIOUS DISEASES | HIV-1 ANTIBODY | PROTECTION | PASSIVE TRANSFER | IMMUNOLOGY | broadly neutralizing antibodies | RESPONSES | vaccine | PLASMA | SPONTANEOUS CONTROLLERS | IMMUNODEFICIENCY-VIRUS TYPE-1 | HUMORAL IMMUNITY | INFECTION | BREADTH | Viral antibodies | Antibodies | Care and treatment | Usage | HIV infection | Vaccination
Journal Article
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 690 - 702
Broadly neutralizing antibodies (bnAbs) to HIV delineate vaccine targets and are prophylactic and therapeutic agents. Some of the most potent bnAbs target a...
broadly neutralizing antibody | HIV | PGT145 | trimer apex | envelope glycoprotein | cryo-electron microscopy | REFINEMENT | SYSTEM | PROTEIN | RECOGNITION | VALIDATION | IMMUNOLOGY | REVEAL | QUATERNARY | BINDING | FEATURES | REGION | Surface Plasmon Resonance | Epitopes - metabolism | env Gene Products, Human Immunodeficiency Virus - immunology | Humans | Protein Multimerization | Antibodies, Neutralizing - metabolism | Crystallography, X-Ray | env Gene Products, Human Immunodeficiency Virus - metabolism | Anions - chemistry | Epitopes - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - immunology | HEK293 Cells | Polysaccharides - chemistry | Protein Domains | env Gene Products, Human Immunodeficiency Virus - chemistry | HIV Antibodies - metabolism | Amino Acid Sequence | HIV-1 - metabolism | Protein Structure, Secondary | Models, Molecular | Polysaccharides - immunology | Protein Binding - immunology | HIV Antibodies - chemistry | Polysaccharides - metabolism | Cryoelectron Microscopy | Sequence Homology, Amino Acid | HIV-1 - immunology | Antibodies, Neutralizing - chemistry | Epitopes - chemistry | Atomic force microscopy | Residues | Immunoglobulins | Quaternary | Envelope protein | Antibodies | Pharmacology | Vaccines | Electron microscopy | Chemical compounds | Transmission electron microscopy | Human immunodeficiency virus--HIV | Neutralizing | Canopies | Atomic structure | Dismantling | Symmetry | Immune system
broadly neutralizing antibody | HIV | PGT145 | trimer apex | envelope glycoprotein | cryo-electron microscopy | REFINEMENT | SYSTEM | PROTEIN | RECOGNITION | VALIDATION | IMMUNOLOGY | REVEAL | QUATERNARY | BINDING | FEATURES | REGION | Surface Plasmon Resonance | Epitopes - metabolism | env Gene Products, Human Immunodeficiency Virus - immunology | Humans | Protein Multimerization | Antibodies, Neutralizing - metabolism | Crystallography, X-Ray | env Gene Products, Human Immunodeficiency Virus - metabolism | Anions - chemistry | Epitopes - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - immunology | HEK293 Cells | Polysaccharides - chemistry | Protein Domains | env Gene Products, Human Immunodeficiency Virus - chemistry | HIV Antibodies - metabolism | Amino Acid Sequence | HIV-1 - metabolism | Protein Structure, Secondary | Models, Molecular | Polysaccharides - immunology | Protein Binding - immunology | HIV Antibodies - chemistry | Polysaccharides - metabolism | Cryoelectron Microscopy | Sequence Homology, Amino Acid | HIV-1 - immunology | Antibodies, Neutralizing - chemistry | Epitopes - chemistry | Atomic force microscopy | Residues | Immunoglobulins | Quaternary | Envelope protein | Antibodies | Pharmacology | Vaccines | Electron microscopy | Chemical compounds | Transmission electron microscopy | Human immunodeficiency virus--HIV | Neutralizing | Canopies | Atomic structure | Dismantling | Symmetry | Immune system
Journal Article
Current HIV/AIDS Reports, ISSN 1548-3568, 2/2016, Volume 13, Issue 1, pp. 31 - 37
Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies...
bNAb | HIV/AIDS | HIV pathogenesis | Medicine & Public Health | HIV | Antibody | Broadly neutralizing antibodies | Reservoir | Review | Eradication | Medicine/Public Health, general | PLASMA RICH | INFECTIOUS DISEASES | HIV-1-INFECTED HUMANS | PASSIVE IMMUNOTHERAPY | TRANSFUSIONS | HUMAN MONOCLONAL-ANTIBODY | AIDS | HUMAN-IMMUNODEFICIENCY-VIRUS | IMMUNIZATION | THERAPY | ENVELOPE | Immunotherapy, Adoptive - methods | Antibodies, Viral - therapeutic use | Humans | Antibodies, Monoclonal - therapeutic use | Epitopes - immunology | HIV Envelope Protein gp120 - immunology | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV-1 - immunology | Antibodies, Neutralizing - therapeutic use | Peptide Fragments - immunology | Binding Sites - immunology | HIV Infections - therapy | Antibodies, Viral - immunology | Viral Envelope Proteins - immunology | Antibodies, Monoclonal - immunology | Monoclonal antibodies | Medical colleges | Control | HIV (Viruses) | Antigenic determinants | HIV Pathogenesis and Treatment (AL Landay, Section Editor)
bNAb | HIV/AIDS | HIV pathogenesis | Medicine & Public Health | HIV | Antibody | Broadly neutralizing antibodies | Reservoir | Review | Eradication | Medicine/Public Health, general | PLASMA RICH | INFECTIOUS DISEASES | HIV-1-INFECTED HUMANS | PASSIVE IMMUNOTHERAPY | TRANSFUSIONS | HUMAN MONOCLONAL-ANTIBODY | AIDS | HUMAN-IMMUNODEFICIENCY-VIRUS | IMMUNIZATION | THERAPY | ENVELOPE | Immunotherapy, Adoptive - methods | Antibodies, Viral - therapeutic use | Humans | Antibodies, Monoclonal - therapeutic use | Epitopes - immunology | HIV Envelope Protein gp120 - immunology | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV-1 - immunology | Antibodies, Neutralizing - therapeutic use | Peptide Fragments - immunology | Binding Sites - immunology | HIV Infections - therapy | Antibodies, Viral - immunology | Viral Envelope Proteins - immunology | Antibodies, Monoclonal - immunology | Monoclonal antibodies | Medical colleges | Control | HIV (Viruses) | Antigenic determinants | HIV Pathogenesis and Treatment (AL Landay, Section Editor)
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 01/2010, Volume 107, Issue 1, pp. 181 - 186
We previously reported that some of the rare broadly reactive, HIV-1 neutralizing antibodies are polyreactive, leading to the hypothesis that induction of...
2F5 | Autoantigens | B cell development | Broadly neutralizing antibodies | autoantigens | MULTIDISCIPLINARY SCIENCES | broadly neutralizing antibodies | IMMUNOGLOBULIN HEAVY | EDITED B-CELLS | EPITOPE | DNA | IMMUNODEFICIENCY-VIRUS TYPE-1 | MICE | SELECTION | EXPRESSION | SELF-TOLERANCE | Recombinant Fusion Proteins - immunology | Humans | Immunoglobulin Variable Region - immunology | Antibodies, Neutralizing - immunology | Immune Tolerance - immunology | Female | Immunoglobulin Heavy Chains - immunology | Cell Line | Mice, Inbred C57BL | B-Lymphocytes - physiology | Mice, Transgenic | Antibodies, Neutralizing - genetics | Spleen - cytology | HIV-1 - genetics | Gene Knock-In Techniques | HIV-1 - immunology | Animals | B-Lymphocytes - immunology | Autoantigens - immunology | Gene Rearrangement | Immune Tolerance - genetics | Recombinant Fusion Proteins - genetics | Immunoglobulin Variable Region - genetics | Mice | Immunoglobulin Heavy Chains - genetics | HIV antibodies | Physiological aspects | Genetic aspects | B cells | Research | Health aspects | Immunological tolerance | Biological Sciences
2F5 | Autoantigens | B cell development | Broadly neutralizing antibodies | autoantigens | MULTIDISCIPLINARY SCIENCES | broadly neutralizing antibodies | IMMUNOGLOBULIN HEAVY | EDITED B-CELLS | EPITOPE | DNA | IMMUNODEFICIENCY-VIRUS TYPE-1 | MICE | SELECTION | EXPRESSION | SELF-TOLERANCE | Recombinant Fusion Proteins - immunology | Humans | Immunoglobulin Variable Region - immunology | Antibodies, Neutralizing - immunology | Immune Tolerance - immunology | Female | Immunoglobulin Heavy Chains - immunology | Cell Line | Mice, Inbred C57BL | B-Lymphocytes - physiology | Mice, Transgenic | Antibodies, Neutralizing - genetics | Spleen - cytology | HIV-1 - genetics | Gene Knock-In Techniques | HIV-1 - immunology | Animals | B-Lymphocytes - immunology | Autoantigens - immunology | Gene Rearrangement | Immune Tolerance - genetics | Recombinant Fusion Proteins - genetics | Immunoglobulin Variable Region - genetics | Mice | Immunoglobulin Heavy Chains - genetics | HIV antibodies | Physiological aspects | Genetic aspects | B cells | Research | Health aspects | Immunological tolerance | Biological Sciences
Journal Article
Virology, ISSN 0042-6822, 2012, Volume 435, Issue 1, pp. 46 - 56
Abstract The need for an effective vaccine to prevent the global spread of human immunodeficiency virus type 1 (HIV-1) is well recognized. Passive immunization...
Infectious Disease | HIV-1 | Vaccine | Envelope glycoprotein | Broadly neutralizing antibodies | ENVELOPE GLYCOPROTEIN TRIMERS | V1/V2 DOMAIN | CRYSTAL-STRUCTURE | GLYCOSYLATION SITES | CROSS-CLADE NEUTRALIZATION | CHIMERIC VIRUS | VIROLOGY | STRUCTURAL BASIS | IMMUNODEFICIENCY-VIRUS TYPE-1 | HUMORAL IMMUNITY | HUMAN MONOCLONAL-ANTIBODIES | Antibodies, Neutralizing | Protein Structure, Tertiary | HIV Infections - prevention & control | env Gene Products, Human Immunodeficiency Virus - immunology | HIV Infections - virology | Humans | AIDS Vaccines - immunology | Antigens, Viral - chemistry | Neutralization Tests | HIV Antibodies - administration & dosage | HIV Antibodies - chemistry | Antigens, Viral - immunology | HIV Infections - immunology | HIV-1 - immunology | Animals | HIV Antibodies - immunology | Immunity, Humoral | Immunization, Passive | AIDS Vaccines - administration & dosage | env Gene Products, Human Immunodeficiency Virus - chemistry | Vaccines | HIV (Viruses) | Health aspects | Antigenic determinants
Infectious Disease | HIV-1 | Vaccine | Envelope glycoprotein | Broadly neutralizing antibodies | ENVELOPE GLYCOPROTEIN TRIMERS | V1/V2 DOMAIN | CRYSTAL-STRUCTURE | GLYCOSYLATION SITES | CROSS-CLADE NEUTRALIZATION | CHIMERIC VIRUS | VIROLOGY | STRUCTURAL BASIS | IMMUNODEFICIENCY-VIRUS TYPE-1 | HUMORAL IMMUNITY | HUMAN MONOCLONAL-ANTIBODIES | Antibodies, Neutralizing | Protein Structure, Tertiary | HIV Infections - prevention & control | env Gene Products, Human Immunodeficiency Virus - immunology | HIV Infections - virology | Humans | AIDS Vaccines - immunology | Antigens, Viral - chemistry | Neutralization Tests | HIV Antibodies - administration & dosage | HIV Antibodies - chemistry | Antigens, Viral - immunology | HIV Infections - immunology | HIV-1 - immunology | Animals | HIV Antibodies - immunology | Immunity, Humoral | Immunization, Passive | AIDS Vaccines - administration & dosage | env Gene Products, Human Immunodeficiency Virus - chemistry | Vaccines | HIV (Viruses) | Health aspects | Antigenic determinants
Journal Article